Company: CGCT
Filing Date: 2025-03-05
Form Type: CORRESP
Source: 0001104659-25-020971
Chunk: 1

Company: Cartesian Growth Corp III
Filing Date: 2025-03-05
Form: CORRESP
Chunk 1
---
 refer to Item 1602(a)(3) of Regulation S-K.       |

: The Company has revised
its disclosure on the cover page and pages 12 and 102 of Amendment No. 1 in response to the Staff’s comment.

U.S. Securities and Exchange Commission

Division of Corporation Finance

March 5, 2025

Page 2

Initial Shareholders Information, page 10

| 2. | Please expand your narrative disclosure to discuss whether the exercise of the private warrants on                                  
 a cashless basis and the conversion of the working capital loans into warrants may result in a material dilution of the purchasers’ 
 equity interests. Please refer to Item 1602(b)(6) of Regulation S-K.                                                                |

: The Company has revised
its disclosure on the cover page and pages 11, 23, 32, 33, 45, 74, 83, 90, 92, 102, 126, 130, 135, and 137 of Amendment No. 1 in response
to the Staff’s comment.

Risk Factors Summary, page 37

| 3. | Please expand the sixth bullet to explain that no vote from public shareholders may be needed if only                                  
 the holders representing a quorum vote their shares, as you discuss elsewhere in your prospectus. Also clarify this information in the 
 header of your last risk factor on page 39.                                                                                            |

: The Company has revised
its disclosure on pages 37 and 39 of Amendment No. 1 in response to the Staff’s comment.

Risk Factors

Risks Relating to our Securities, page 68

| 4. | We note your discussion on pages 77 and 78 regarding the U.S. federal excise tax. Where you discuss                                      
 that the excise tax could reduce the amount of cash available to transfer to the target business in connection with our initial business 
 combination, please revise to also clarify that it could also reduce the amount of cash available to pay redemptions.                    |

: The Company has revised
its disclosure on page 78 of Amendment No. 1 in response to the Staff’s comment.

Underwriting, page 166

| 5. | We note your disclosure on page 22 that the private placement warrants to be purchased by Cantor are                             
 deemed by FINRA to be underwriters’ compensation. Please revise to include the private placement warrants in your description of 
 the underwriter’s compensation. Refer to